TC-99(M)-TETROFOSMIN SCINTIGRAPHY IN HODGKINS-DISEASE

The aim of this study was to assess the suitability of Tc-99(m)-tetrof osmin (tetrofosmin) scintigraphy as a diagnostic modality in patients with Hodgkin's disease. Fourteen untreated patients with biopsy proven Hodgkin's disease (clinical stage Ia-IVb) were investigated. Post-tre atment investigations were also done in 7 of the 14 patients. Focal pa thological tetrofosmin uptake was seen in 42 sites in the pre-treatmen t studies. Computed tomography identified 36 pathological regions. The tumour-to-background ratio ranged from 7.44 to 2.17 (mean 1.63). Foll ow-up studies demonstrated a response to treatment, in that there was a reduction in, or complete disappearance of, localized tetrofosmin up take in regions previously pathological, and a decrease in tumour-to-b ackground ratios. Tetrofosmin appears suitable for the localization of lymphomatous lesions, especially supradiaphragmatic ones, and for the follow-up of therapeutic response.